Trial Profile
An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma With Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Bleomycin; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Prednisolone; Prednisone; Vinblastine; Vincristine
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms KEYNOTE-667
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 12 Dec 2023 Updated results (n=62) for pts with high-risk cHL and SER, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Interim Results of pts with low-risk cHL, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Oct 2023 Status changed from recruiting to active, no longer recruiting.